Lanreotideautogel/depot may be safe for intestinal & pancreatic tumor control: 3 study insights

Lanreotideautogel/depot may be a safe management technique for patients with metastatic intestinal and pancreatic neuroendocrine tumors, according to research presented at the 2017 Gastrointestinal Cancers Symposium.

Here's what you need to know:

1. Of the 378 patients in the five lanreotideautogel/depot trials the researchers pooled data from, 90 percent received lanreotideautogel/depot of 120 milligrams.

2. The adverse event profiles were overall similar across all of the studies; the most commonly reported adverse event were GI events (56 percent).

3. There were no study withdrawals due to GI adverse events and no deaths in the studies were considered treatment-related.

The researchers concluded: "This comprehensive safety analysis supports the positive benefit–risk profile of LAN both for CS control in symptomatic NET and for tumor control in metastatic intestinal/pancreatic NET."

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Learning Opportunities

Featured Webinars

Featured Whitepapers

Featured Podcast